Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Guangjian, Yang"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-7 (2024)
Abstract Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare subtype of inflammatory myofibroblastic tumor, characterized to be an aggressive disease with high frequency of ALK rearrangement, rapid recurrence, and poor prognosis. Primar
Externí odkaz:
https://doaj.org/article/81268a47bb3c4a13aac672d12b7e0003
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Naïve CD4+ T cells and their differentiated counterparts play a significant regulatory role in the tumor immune microenvironment, yet their effects on lung adenocarcinoma (LUAD) are not fully understood. Methods We utilized Mende
Externí odkaz:
https://doaj.org/article/535d804a3a1541c5bfefac05d46a4e55
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Background Unlike human epidermal growth factor receptor 2 (HER2) amplification or exon 20 insertions, missense mutations in the extracellular domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) of the HER2 protein have
Externí odkaz:
https://doaj.org/article/d225a87f030b47eaa548997d81f75222
Autor:
Xiaoyan Yin, Wanqi Zhu, Xiaoyong Tang, Guangjian Yang, Xianguang Zhao, Kaikai Zhao, Liyang Jiang, Xiaolin Li, Hong Zhao, Xin Wang, Yuanyuan Yan, Ligang Xing, Jinming Yu, Xiangjiao Meng, Hanxi Zhao
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The antiviral drug Nirmatrelvir was found to be a key drug in controlling the progression of pneumonia during the infectious phase of COVID-19. However, there are very few options for effective treatment for cancer patients who ha
Externí odkaz:
https://doaj.org/article/0e2670b4d7b944589620ccd3cd6ab283
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-6 (2024)
Abstract Anaplastic lymphoma kinase (ALK) gene fusion is a classic driver mutation in non-small cell lung cancer (NSCLC); however, ALK double-fusion variants in NSCLC have rarely been reported. In this study, we reported a case with extremely uncommo
Externí odkaz:
https://doaj.org/article/f0fbe4cd8d744e7180f371f5bf696231
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e30312- (2024)
A775_G776insYVMA, the typical and predominant HER2 exon 20 insertion variant in non-small cell lung cancer, exhibits relative insensitivity to covalent HER2-targeted tyrosine kinase inhibitors. However, other less common insertions have shown better
Externí odkaz:
https://doaj.org/article/1c07e257f4354db0be44f596c74d1d84
Autor:
Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Xin Ai, Siyu Lei, Haiyan Xu, Yan Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3275-3281 (2023)
Abstract Background Although some targeted therapies have been shown to be effective in treating HER2‐altered non‐small cell lung cancer (NSCLC), the survival demands have not yet been met due to the high cost and limited availability. This study
Externí odkaz:
https://doaj.org/article/07bdfe03836746a9bfff7fd173e5061a
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19438-19448 (2023)
Abstract Objectives The purpose of this study was to explore the efficacy and safety of toripalimab combined with anlotinib in patients with advanced non‐small cell lung cancer (NSCLC) who acquired resistance to epidermal growth factor receptor tyr
Externí odkaz:
https://doaj.org/article/8d290b90eb984770bc5c99d738ee84a5
Autor:
Guangjian Yang, Yaning Yang, Runze Liu, Weihua Li, Haiyan Xu, Xuezhi Hao, Junling Li, Shuyang Zhang, Fei Xu, Siyu Lei, Yan Wang
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 335-344 (2023)
Abstract Background Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity. Compared with standar
Externí odkaz:
https://doaj.org/article/f9f7c6acb34447dcbd715589efc90172
Autor:
Yaning Yang, Xin Ai, Haiyan Xu, Guangjian Yang, Lu Yang, Xuezhi Hao, Ke Yang, Yuling Mi, Guizhen Wang, Shuyang Zhang, Siyu Lei, Yan Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 23, Pp 3295-3303 (2022)
Abstract Background The application of immune checkpoint inhibitors (ICIs) represents a breakthrough in the current landscape for the treatment of extensive‐stage small‐cell lung cancer (ES‐SCLC), but the real‐world outcome is limited. This s
Externí odkaz:
https://doaj.org/article/08e1341961ba43ef821000a62ab18405